T he role of estrogens in the cardiovascular system extends beyond their function as vasoactive hormones, because we and others have shown that estrogen receptor activation attenuates cardiac hypertrophy and adverse remodeling also by blood pressure-independent mechanisms.
T he role of estrogens in the cardiovascular system extends beyond their function as vasoactive hormones, because we and others have shown that estrogen receptor activation attenuates cardiac hypertrophy and adverse remodeling also by blood pressure-independent mechanisms. [1] [2] [3] Afterloadindependent cardiac hypertrophy arises also from impaired cardiac glucose uptake and metabolism. Cardiac glucose metabolism is, thus, not only pivotal to maintain contractile function but also coregulates pathological cardiac growth. Indeed, glucose oxidation carries a lower oxygen demand for ATP generation and results in decreased generation of reactive oxygen species compared with fatty acid metabolism. 4, 5 The biological functions of estrogens are mediated via 2 distinct nuclear hormone receptors, termed "estrogen receptor-α" (ERα) and "estrogen receptor-β" (ERβ). Pharmacological studies using subtype-selective ERα and ERβ agonists, as well as the phenotype of ERα-and ERβ-deficient mice, provide clear evidence for a cardioprotective function of both receptor subtypes. These include protection against ischemia/ reperfusion injury that is aggravated in mice lacking the ERα receptor (ERKO) 6, 7 and increased mortality and aggravation of heart failure after experimental myocardial infarction in ERβ-deficient mice, 8 as well as loss of estrogen protection against left ventricular hypertrophy in ERβ-deficient mice. 9 Pharmacological studies using nonselective (17β-estradiol) or subtype-selective ERα (16α-LE2) and ERβ agonists (8β-VE2) have already proven the concept that ligand-dependent activation of ERα or ERβ protects the heart against cardiac hypertrophy by afterload-independent 10 and -dependent 11 mechanisms. Within the context of afterload-independent mechanisms of cardiac hypertrophy, it is interesting to note that the ERα coregulates systemic glucose uptake and homeostasis by complex mechanisms, as evidenced by the development of obesity in ageing ERKO mice. 12 To cope with energy demand, the heart adapts its energy substrate preference according to substrate availability and the presence of stresses, such as exercise, fasting, and ischemia. Limitation of the cardiac metabolic flexibility may affect the proper energy delivery to the myocardium and results in exacerbation of cardiac dysfunction. 13 Although cardiac glucose uptake affects cardiac function and despite
The Estrogen Receptor-α Is Required and Sufficient to Maintain Physiological Glucose Uptake in the Mouse Heart
the fact that glucose uptake and use of the heart coregulate cardiac hypertrophy and function, the roles of estrogens and of specific estrogen receptor subtypes in cardiac glucose uptake have not yet been determined. As shown here for the first time, ERα is sufficient and required to maintain physiological cardiac glucose uptake in normotensive female mice.
Materials and Methods
Please see the online-only Data Supplement for an expanded Material and Methods section. The study was approved by the Institutional Animal Research Committee. All of the animals were kept under standard conditions at the animal facility of the University of Wurzburg.
Pharmacological Studies
Twelve-week-old female C57BL/6 mice (Harlan) were anesthetized with isoflurane (isoflurane 1.5 vol% supplemented by 0.5 L of oxygen per minute) and sham operated or ovariectomized and implanted with micro-osmotic pumps filled either with placebo-carrier solution ([2-hydroxypropyl]-β-cyclodextrine 23 mg/mL in water; Sigma Aldrich Chemical, St Louis, MO), the nonsubtype selective ER ligand 17β-estradiol ([2-hydroxypropyl]-β-cyclodextrine encapsulated at a doses of 2 μg/kg per day) as reported by Andersson et al, 14 or the ERα selective ligand 16α-LE2 ([2-hydroxypropyl]-β-cyclodextrine encapsulated at a doses of 100 μg/kg per day; Bayer Pharma AG, Berlin, Germany). After 22 days of treatment, animals were submitted to 18 F-fluorodeoxyglucose (FDG)-small animal positron emission tomography (PET), glucose tolerance test, echocardiography, or hemodynamic analysis. Organs were collected 2 days later after 30 minutes of glucose load. Hearts were arrested using cold KCl solution, fixed at −80°C in OCT Tissue Teck (Sakura), and divided in transversal sections for protein and RNA analysis.
Studies in ER-α Knockout and Wild-Type Mice
Female ERKO mice at the age of 12 weeks obtained from Taconics reserve were provided from National Institute of Environmental Health Sciences (Research Triangle Park, NC). ERKO (n=9) and wild-type (WT) littermates (n=6) and were kept for 22 days, fasted overnight, and submitted to FDG-PET. Animals were euthanized 4 days later for organ collection.
Statistics
Results are presented as mean±SEM. Multigroup comparisons were done by 1-way or 2-way ANOVA, followed by Student-NewmanKeuls post hoc all pairwise testing using the Sigma Stat 2.03 software. P values <0.05 were considered significant.
Results

PET Analysis of Cardiac FDG Uptake in Female Mice: Pharmacological Studies
Cardiac FDG uptake was significantly lower in ovariectomized WT compared with sham-operated female mice (−40.9%; P<0.05; n=11; Figure 1 and Table 1 ). Long-term treatment with the nonsubtype selective estrogen receptor agonist 17β-estradiol or the selective ERα agonist 16α-LE2 fully restored impaired cardiac FDG uptake in ovariectomized mice. In contrast, hepatic FDG uptake was comparable and not statistically different among all of the treatment groups. Blood glucose levels under fasting conditions before FDG-PET were not different among all of the animals. A comparable and transient rise of blood glucose was registered after the initial glucose bolus in all of the animals. Blood glucose levels were uniform and not different among all of the animals at the time when FDG-PET images were obtained (Table 1) .
PET Analysis of Cardiac FDG Uptake in Female ERKO and WT Mice
Cardiac FDG uptake was significantly lower in female ERKO mice compared with WT littermates (−53.8%; P<0.05; n=7; Figure 1 and Table 2 ). In contrast, hepatic FDG uptake did not differ between both genotypes. Fasting glucose was significantly higher in ERKO compared with WT mice. However, serum glucose levels were no longer different between both genotypes after the initial glucose bolus and at the time when PET images were acquired (Table 2) . 
Hypertension
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Systemic Glucose Tolerance Tests and Serum Insulin Levels
Blood glucose levels increased to comparable levels after IP glucose administration among intact, ovariectomized, and estradiol-treated mice (P>0.05; n=6-8; Figure 2 ). The time course until blood glucose levels fell back to baseline levels was also not different among all of the treatment groups. Insulin serum levels after fasting and under glucose load were not different among intact, ovariectomized, and estradioltreated mice at baseline and after glucose challenge (Table 1) . Serum insulin levels were lower in 16α-LE2-treated mice at baseline and after glucose load (Table 1) .
Morphometry
Uterus atrophy and increased body weight were observed in ovariectomized WT mice compared with sham-operated mice. Estradiol supplementation or 16-LE2 treatment prevented uterus atrophy and gain of body weight that occurred in ovariectomized mice ( 
Invasive Hemodynamics and Echocardiography
Left ventricular intracavitary dimensions and global left ventricular function as determined by echocardiography, as well as hemodynamic parameters, including, heart rate, and blood pressure levels, were not statistically different among all of the treatment groups (Table 1) .
Affymetrix Analyses of Cardiac mRNA Expression
Microarray comparisons were done between total RNA from heart samples of ovariectomized mice treated with placebo, against heart samples of mice treated with 17β-estradiol or 16α-LE2, with a fold change threshold of 1.5 and a P value <0.001. A total of 95 transcripts were differentially expressed in estradiol-treated mice, and 322 transcripts showed differential accumulation in 16α-LE2-treated mice compared with placebo treatment. Among these, 17 transcripts were downregulated, and 10 transcripts were collectively upregulated F-fluorodeoxyglucose positron emission tomography; % ID heart, percentage of injected dose in the whole heart; SUV, standardized uptake value; myo, myocardium; dcy, decay corrected yield; HR, heart rate; SAP, systolic aortic pressure; DAP, diastolic aortic pressure; MAP, calculated mean aortic pressure; LVESA, left ventricular end-systolic area; LVEDA, left ventricular end-diastolic area; FS, fractional shortening. 
Quantitative Real-Time PCR Array Analyses
A more focused search was conducted among mRNAs encoding proteins specifically related to glucose uptake and metabolism (Table 3) . Across a panel of 84 genes involved in regulation and enzymatic pathways of glucose and glycogen metabolism, a cluster of 32 genes involved in glycolysis and the tricarboxylic acid cycle was expressed at higher levels in ovariectomized animals receiving 16α-LE2 compared with placebo. Among these, 6 genes, including aldolase A and B, citrate synthase, and succinate-dehydrogenase subunit B, were upregulated at mRNA level by estradiol and 16α-LE2 compared with placebo.
Discussion
Sex differences in the development of cardiovascular disease have been attributed in part to beneficial effects of female sex hormones, in particular to estrogens. Although altered cardiac glucose and fatty acid metabolism play important roles in cardiac function, cardiac hypertrophy, and heart failure, the question of whether estrogens and, in particular, ERα modulate cardiac glucose uptake in vivo has not yet been specifically addressed. Thus, the current study shows for the first time that 17β-estradiol fully prevents the decrease of cardiac glucose uptake in ovariectomized mice and that ERα estrogen receptors are sufficient and required to maintain physiological levels of cardiac glucose uptake in normotensive female mice.
The absence of ovarian hormones not only increases body mass but may also affect systemic glucose and fatty acid metabolism. 15 Therefore, impaired cardiac FDG uptake in ovariectomized compared with gonadal intact animals might have resulted from alterations of systemic glucose homeostasis, because elevated serum glucose levels might have competed with FDG during cardiac PET imaging. Although ovariectomized mice showed increased body mass, serum glucose and serum insulin levels were not significantly altered among intact, ovariectomized, and estradiol-treated mice. These data, together with unaltered systemic glucose tolerance as determined by IP glucose tolerance test, do not support such a mechanism. Instead, it appears more likely that cardiac FDG uptake is more efficient in estradiol-treated mice. In vivo FDG-PET imaging allowed us to show that liver FDG uptake was comparable and not different among shamoperated, ovariectomized, and estradiol-supplemented female mice. Together, these findings are consistent with the hypothesis that 17β-estradiol regulates cardiac glucose uptake in an organ-specific manner and, at least in part, independent of systemic glucose levels.
17β-Estradiol as the predominant endogenous estrogen has proven functions in the cardiovascular system that includes vasodilatation, blood pressure reduction, prevention of cardiac hypertrophy, and attenuation of chronic heart failure. [1] [2] [3] Because cardiovascular pathology is frequently linked to altered glucose uptake and metabolism, it is interesting to note that supplementation of physiological estradiol doses completely prevented the decrease of cardiac FDG uptake that was observed in ovariectomized mice receiving placebo. Our findings are in good agreement with previous studies that addressed the role of estrogens in cardiac glucose metabolism by measuring cardiac gene expression and enzyme activities related to glucose metabolism. [16] [17] [18] However, the current report is the first to prove this concept under vivo conditions. The biological functions of estrogens are transmitted by 2 distinct estrogen receptor subtypes, ERα and ERβ. Both ER subtypes exhibit tissue-specific expression profiles and regulate divergent, as well as redundant, functions. For instance, both receptor subtypes attenuate cardiovascular remodeling in aldosterone salt-treated rats, 19 but it is specifically the ERβ receptor that lowers elevated blood pressure in spontaneous hypertensive rats. 10, 11 Because 17β-estradiol acts as a pure agonist on both estrogen receptor subtypes, we used the highly selective ERα agonist 16α-LE2 to determine whether activation of a specific estrogen receptor subtype might be sufficient to restore impaired cardiac FDG uptake in ovariectomized mice. As reported here, the selective ERα agonist 16α-LE2 fully prevented the decrease of cardiac FDG uptake that occurred in ovariectomized mice receiving placebo. Because it is known that the current dose of 16α-LE2 (100 μg/kg of body weight) does not activate the ERβ receptor to a measurable extent, coactivation of ERβ receptors appears as an unlikely explanation for improved cardiac FDG uptake. 20, 21 Although estradiol and 16α-LE2 maintained cardiac FDG uptake in ovariectomized mice, we could not directly compare the pharmacological efficacy of both ligands, because estradiol was dosed to achieve physiological serum hormone levels, whereas 16α-LE2 was dosed at submaximal pharmacological levels at which the compound activates ERα but not yet ERβ to a measurable extent. 20 Another interesting aspect was the observation that 16α-LE2-treated mice showed physiological cardiac FDG uptake despite lower insulin serum levels compared with gonadal-intact or estradiol-treated mice. Thus, we can rule out that 16α-LE2 promotes cardiac FDG uptake merely via enhanced insulin secretion and/or decreased insulin elimination. However, we cannot formally rule out that 16α-LE2 might enhance insulin-dependent cardiac glucose uptake by mechanism(s) downstream of insulin bioavailability. Taken together, our current observations indicate that pharmacological activation of the ERα receptor is fully sufficient to maintain physiological cardiac glucose uptake in ovariectomized mice independent of serum insulin levels.
To substantiate this interpretation and to test whether activation of ERα would be required to maintain physiological cardiac glucose uptake, we compared cardiac FDG uptake among female mice lacking the ERα receptor (ERKO Chapel Hill ) and WT littermates. ERKO mice develop decreased metabolic rates, impaired glucose tolerance, skeletal muscle insulin resistance, and obesity with ageing. 12, 22 In this study we used young adult ERKO mice that were age matched with animals evaluated in the pharmacological study. In these ERKO mice, cardiac FDG uptake was significantly impaired in comparison with their WT littermates. This observation supports the hypothesis that activation of ERα is not only sufficient but that ERα is required to maintain physiological cardiac glucose uptake in normotensive female mice. In contrast to the heart, liver FDG uptake was uniform and not different among WT and ERKO mice. These findings further support the interpretation that ERα regulates glucose uptake in an organ-specific manner. However, cardiac FDG uptake could not be compared directly among pharmacological and genetic studies because the different genetic background of both lines affected absolute levels of cardiac FDG uptake. Similar observations, within a different context, have been reported before by Berglund et al. 23 Based on the current findings, one might speculate that ERβ might be dispensable for estrogens to regulate cardiac glucose uptake. The current data and the phenotype of mice lacking ERβ provide some preliminary support for such a hypothesis because body weight and adipose tissue mass do not differ among ERβ-deficient mice and WT mice. 24 On the other hand, glucose uptake of skeletal muscle has been reported to be impaired in ERβ-deficient mice compared with WT mice. 25 Further studies in ERβ-deficient mice, which were not the focus of this study, will be required to solve the question of whether ERβ coregulates cardiac glucose uptake.
Affymetrix and quantitative RT-PCR analysis revealed lower expression levels of Ppargc1 in hormone-treated compared with estrogen-depleted mice. PGC-1a (Peroxisome proliferator-activated receptor gamma coactivator alpha) participates in cardiac energy substrate regulation by promoting fatty acid oxidation and reducing glucose oxidation. Increased cardiac FDG uptake in response to estrogen treatment is thus in line with the known function of PGC-1α 26 and with reports on transcriptional control of cardiac PGC1α expression by estrogens. 27, 28 The current study extends these reports toward the in vivo situation and the specific role of ERα. In addition, treatment with 16α-LE2 diminished mRNA levels encoding the Sparc, which promotes cardiac fibrosis and has rising expression with increased body mass. 29 However, Sparc expression levels are unlikely to explain improved cardiac glucose uptake in estrogen-treated mice.
Further analyses among genes specifically related to glucose metabolism by quantitative RT-PCR array evaluation demonstrated a significant upregulation of several genes with defined function in glycolysis and glucose metabolism. Among the transcripts that were upregulated by 17β-estradiol and by 16α-LE2 were aldolase A and B, which catalyze the conversion of fructose 1,6-bisphosphate to dihydroxyacetone phosphate and Glyceraldehyde phosphate dehydrogenase (GAP). 16α-LE2 also upregulated hexokinase 2 and 3, which act downstream of cardiac glucose transporters (glut1 and glut4) by phosphorylating cell membranepermeable glucose to impermeable glucose 6-phosphate. Also, mRNAs encoding enzymes of the tricarboxylic acid cycle, such as citrate synthase, fumarate hydratase I, and succinate dehydrogenase complex (subunit B), were significantly more abundant in hormone compared with placebotreated mice. Of note, mRNA levels of several genes varied substantially with the estrus cycle and endogenous estrogen Summary of 3 independent comparisons among ovariectomized mice treated with placebo vs sham animals or mice treated with 17β-estradiol or 16α-LE2. Data analysis was performed using the manufacturer's integrated Web-based software package for the PCR Array System (Sabiosciences-Qiagen) using ∆∆Ct-based foldchange calculations.
by guest on May 30, 2017 http://hyper.ahajournals.org/ Downloaded from levels among sham-operated mice compared with ovariectomized animals receiving placebo, estradiol, or 16α-LE2. This interpretation is substantiated by positive and close correlations between uterine mass and cardiac mRNA levels of several genes, including hexokinase 2 and citrate synthase.
Because global cardiac function was not impaired in ovariectomized mice, it appears tempting to speculate that decreased cardiac glucose uptake might have been compensated by an increase of myocardial fatty acid uptake and metabolism to preserve mitochondrial function and ATP generation. However, cardiac fatty acid uptake and mitochondrial function were not assessed in this study. Further studies will thus be required to specifically address these questions.
Together, our findings indicate that estrogens regulate cardiac glucose uptake and metabolism in a complex and coordinated fashion. Further and more specific studies will be required to identify the underlying key regulating factors that connect estrogen signaling and cardiac energy substrate regulation.
Perspectives
Here we show that ERα estrogen receptors are sufficient and required to maintain physiological cardiac glucose uptake in normotensive and nondiabetic female mice. Further studies might now be directed toward the unresolved question of whether ERα receptors improve cardiac glucose uptake and use also under conditions of increased cardiac afterload and in type 2 diabetes mellitus. Another important aspect would be to define the role of ERβ receptors in cardiac energy substrate uptake and metabolism, which is still unknown. 
PHYSIOLOGICAL GLUCOSE UPTAKE IN THE MOUSE HEART
Arias-Loza Paula-Anahi PhD. During the tracer uptake period and imaging, the animals were kept anesthetized with tribromoethanol. Blood glucose levels were measured before i.p. glucose injection, before FDG injection and before start of the PET scan using an Accutrend sensor (Roche, Germany). PET data were acquired in list mode, binned into one 10-min time frame, and reconstructed using an interactive ordered-subset expectation maximization algorithm. Image files were analyzed using the public domain tool Amide (1).
Four small, same-size box shaped volumes of interest (VOIs) were assigned to left ventricular myocardium, an additional bigger ellipsoid VOI was set to include the whole left ventricular myocardium. Furthermore another box shaped VOI was assigned to the liver. In order to correct for differences in injected dose and body weight, standardized uptake values were calculated using the formula:
injected dose (MBq) /body weight (g) A tissue density of 1 was assumed. To calculate the SUV of the myocardium, the mean of the four small VOIs was used. Additionally the FDG uptake in whole left ventricle was assessed with the big ellipsoid VOI and expressed as percent of the injected dose (%ID).
Intraperitoneal glucose tolerance test (IGPTT)
Separate sets of 6 animals per group were fasted overnight after 22 days of treatment and received tribromoethanol anesthesia (250 mg/kg i.p.) before assessment of systemic glucose tolerance. Blood glucose was measured immediately before and 10, 20, 30, 40, 50 and 60 minutes after intra peritoneal glucose injection (1.5 g/kg body weight as 20% solution). Glucose concentrations were measured in blood tail samples using an "Accutrend" sensor (Roche, Germany).
Echocardiography and Hemodynamic Measurements
Echocardiography was performed on a Toshiba Power Vision 6000 system with a 15-MHz ultrasound probe under light isoflurane anesthesia and spontaneous respiration (isoflurane 1.5 vol% supplemented by 0.5 L of oxygen per minute). 2D left-parasternal short-axis views at the level of the papillary muscles were recorded. LV end-systolic and end-diastolic areas were calculated by manual tracings of the endocardial border followed by planimetry with the NICE software package (Toshiba Medical Systems). Simultaneous transversal M-mode tracings were recorded with the cursor placed in the middle of the LV cavity. Hemodynamic measurements were performed according to published protocols (2) under isoflurane anesthesia (isoflurane 1.5 vol% supplemented by 0.5 L of oxygen per minute). Both analysis were made in a separate set of 6-8 animals per group and were performed by a single trained investigator blinded to treatment.
Organ collection and measurements of serum insulin levels Animals were fasted overnight after 22 days of treatment, received i.p. injections of glucose (1.5 mg/kg body weight) and were euthanized 30 minutes after glucose challenge. Trunk blood was collected and serum insulin concentrations were measured by RIA using a rat insulin standard (DRG, Germany). Heart and uterus were collected and weighted. Heart samples were arrested using cold KCl solution, fixed at -80°C in OCT Tissue Teck (Sakura) and divided in transversal sections for protein and RNA analysis. Insulin serum levels under fasting conditions without glucose loading were measured in separate sets of 6-8 animals per treatment group.
RNA preparation
Frozen heart blocks were briefly washed in cold NaCl 0.9% solution and total RNA was prepared using the TRIzol Reagent, according to manufacturer instructions (Invitrogen). RNA extract for qRT-PCR were prepared using the RNeasy fibrous tissue Mini kit (Qiagen) according to manufacturer instructions.
Microarrays data analysis
Microarray comparisons were done between total RNA from heart samples of ovarectomized mice treated with placebo, against heart samples of mice treated with 17ß-estradiol or 16α-LE2. Reverse transcription, second-strand synthesis, synthesis of biotin-labeled cRNA and cleanup of double-stranded cDNA were performed according to the Affymetrix protocols (3' IVT express Kit, Affymetrix, Santa Clara, CA) starting from 150 ng of total RNA. Distribution of cRNA fragment sizes was determined by gel electrophoresis (BioAnalyzer, Agilent, Santa Clara, CA). 15 µg of fragmented cRNA were used for hybridization to Mice Genome ® 230 2.0 Arrays (Affymetrix). Data were analyzed using different R packages from the Bioconductor project (www.bioconductor.org). Resulting signal intensities were normalized by variance stabilization (3) . Statistical analysis to select differentially expressed genes was performed using the Limma (Linear Models for Microarray Analysis) package (4) . Considering that increase cardiac glucose uptake was a shared effect for both ligands, we manually searched for redundantly regulated transcripts by 17ß-estradiol and 16α-LE2 of at least 1.5-fold and p significance of 0.001 or lower. Microarray data was submitted to the NCBI gene expression and hybridization array data repository (GEO), accession number GSE34807.
Real-Time Reverse Transcriptase-Polymerase Chain Reaction. RNA samples from mice heart were extracted as described in the "Microarray data analysis" section. After the synthesis of cDNA with random hexamers (iScript kit, BioRad, Germany), a real-time PCR was performed (iCycler, BioRad, Germany) with commercially available TaqMan probes for GAPDH, Slc2a1, Sparc Ppargc1a and Ptgds (Applied Biosystems, U.S.A.). PCR parameters were as recommended for the TaqMan universal PCR master mix kit (Applied Biosystems, U.S.A.). RNA samples were normalized to GAPDH mRNA.
Real-Time PCR gene array. 0,5μg of RNA was reverse transcribed with the RT2 First strand kit (Sabiosciences-Qiagen). Real-time PCR was then performed on each sample using the RT2Profiler PAMM-006A PCR (Sabiosciences-Qiagen) array for mice according to manufacturer instructions. This array allows the evaluation of 84 glucose metabolism related genes in respect to 6 housekeeping genes. A complete list of the genes analyzed is available online at: http://www.sabiosciences.com/rt_pcr_product/HTML/PAMM-006Z.html Data analysis was performed using the manufacturer's integrated web-based software package for the PCR Array System using ΔΔCt based fold-change calculations. Table S1 . Data represent 5 independent experiments in ovarectomized mice receiving placebo versus 17ß-estradiol or 16α-LE2.
